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A B S T R A C T
Cancer treatment, in particular radiotherapy and chemotherapy, is often hindered by an inherent resistance of
cancer cells. Cancer stem cells in particular have previously been shown to be more resistant than other cells
within a tumor and are thought repopulate the tumour after therapies. Therefore, it is of utmost importance to
develop tools and techniques that can be used to study mechanisms of resistance of cancer stem cells as potential
treatment targets. Organoids (and cancer-derived organoids), are three-dimensional tissue-resembling cellular
clusters derived from tissue or tumor speciﬁc stem cells that mimic the in vivo (tumor) characteristics, as well as
(tumor) cell heterogeneity. Cancer organoids may further enhance the in vitro and in vivo models that are cur-
rently available, improve our understanding of cancer stem cell resistance and can be used to develop novel
cancer treatments by improved targeting of cancer stem cells. In this review, we compare organoids with the
more traditional laboratory models, such as cell lines and xenografts, and review the literature of the current role
of cancer organoids in determining treatment responses.
1. Introduction
Cancer is a major health problem, with 14.1 million new cases and
8.2 million deaths due to cancer worldwide in 2012 alone [1]. The
annual number of new cases is estimated to rise to 22.2 million by the
year 2030 [2]. Therefore, it is necessary to continually advance and
develop cancer treatments, to better cope with increasing numbers of
patients and to attain a better level of patient quality of life post-
treatment. The three oldest and most common cancer treatment mod-
alities are based on surgery [3], chemotherapy [4] and radiotherapy
[5], with more modern treatments, such as immunotherapy [6–8],
being developed.
While these treatment modalities are highly successful in treating
many forms of cancer, unfortunately they are not successful in all cases.
Even tumors within tissue of the same origin, the eﬀect of treatment
varies between patients. For example, the standard of care for eso-
phageal cancer in the Netherlands currently consists of neoadjuvant
chemoradiotherapy followed by esophageal resection, as this sig-
niﬁcantly increases disease-free and overall survival compared to sur-
gery alone [9,10]. Furthermore, less locoregional recurrences occur in
patients who undergo neoadjuvant chemoradiotherapy than surgery
alone [11]. However, neoadjuvant chemoradiotherapy already results
in a pathologic complete response in about 25% of these patients in
whom surgery may thus be omitted [10,12]. Conversely, approximately
20% do not respond to neoadjuvant chemoradiotherapy (nCRT) and
would probably beneﬁt from early surgery [10,12] or alternative
treatment. However, the current imaging tools (such as positron-emis-
sion and computed tomography (PET-CT) techniques) to identify these
two patient groups prior to treatment are still unable to predict re-
sponse with reliable accuracy [13–15], and as a result 25% of these
patients either undergo unnecessary surgery or ineﬀective preoperative
chemoradiotherapy (20%). Therefore, better models to predict the
treatment response of esophageal cancer and other cancers with the
required accuracy are essential towards a more individualized treat-
ment of patients (Table 1).
Understanding the response of cancer stem cells to treatment may
be key to a more accurate and complete response prediction to many
cancer treatments. Although the existence and origin of cancer stem
cells is often debated [16–19], many groups have identiﬁed populations
of cells within cancers with cancer stem cell (or at the very least cancer
stem-like) characteristics [20–24]. Cancer stem cells possess many si-
milar characteristics to normal tissue stem cells, in that they are capable
of dividing to symmetrically (giving rise to new stem cells) and asym-
metric divisions giving rise to diﬀerentiated cells of the tumor [18,19].
However, in terms of treatment, possibly the most important property
of the cancer stem cells is, in general, an increased resistance to
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therapies, including radiotherapy [18,19]. Moreover, cancer stem cells
are prone to undergo epithelial-mesenchymal transition (EMT) re-
sulting in migration and mesenchymal-epithelial transition (MET) when
they have found their new niche, thus causing metastasis [25,26].
Therefore, eliminating cancer stem cells during treatment is essential to
overall long-term treatment outcome, as residual cancer stem cells have
the capacity to regenerate a tumor following treatment and furthermore
to metastasize.
2. Current laboratory techniques to assess treatment responses
Currently, many techniques are being used in attempts to elucidate
cancer drug responses, and in particular the response of cancer stem
cells. These techniques include cancer cell lines, organotypic tissue slice
cultures, patient-derived xenografts and organoid culturing. Each of
these techniques have their own advantages, but also their dis-
advantages (some advantages/disadvantages are depicted in Fig. 1).
Selection of the correct tool to use in the laboratory can depend on the
question on hand, but also on the resources (and knowledge) available.
2.1. Cell lines
Established cell lines are probably the most common and well-es-
tablished of these techniques. There are many advantages to using es-
tablished cell lines. They are easier (and cheaper) to maintain than most
other in vitro models, they can easily be manipulated genetically, while
they are also amenable to easy imaging. Techniques to determine sen-
sitivity to drugs and/or irradiation are well-established [27,28], and
thus cell lines facilitate high throughput screening of many drugs and
compounds in a short period of time.
However, traditional two-dimensional (2-D) culture models lack
many crucial signaling factors, such as cell-cell and cell-matrix inter-
actions, which contribute to essential cellular functions in proliferation,
diﬀerentiation and survival [29,30]. Thus, the read-outs of conven-
tional two-dimensional models often misestimate the in vivo response to
therapies [29]. Additionally, cell lines are generally derived from single
cells and therefore do not recapitulate the complete diversity of tumors,
which often consist of many diﬀerent cell types [31], potentially with
diﬀerent treatment sensitivities and even multiple diﬀerent cancer stem
cells. Some of these shortcomings can be overcome by culturing as
spheres/spheroids in an extracellular matrix as this introduces more
‘realistic’ cell-cell interactions [30,32]. However while many groups
have identiﬁed populations with cancer stem-like properties in cell lines
[20,33–35], true cancer stem cells (or at least the diversity of cancer
stem cells in a tumor) are more diﬃcult to identify. Furthermore, cru-
cial factors (such as immune cells, stromal cells and blood vessels) are
missing from cell culture models.
2.2. Patient-derived xenografts
Patient-derived xenografts entails the engraftment of cancerous cells
or tissues into immunodeﬁcient mice. Patient-derived xenograft models
have been established for many cancer types, including colorectal
[36,37], pancreatic [38] and gastric [36] cancers, and can be both
subcutaneously or orthotopically transplanted. Orthotopic transplan-
tation is thought to better resemble the true environment than sub-
cutaneous transplantation [39]. This in vivo model allows for vascu-
larization of the engrafted cells or tissue, while also enabling for the
cells to assemble in a realistic tumor structure and environment in-
cluding hypoxia, an important determent of radiation response [40,41].
These models allow for determination of a patient-speciﬁc response, as
the engraftments can be obtained direct from biopsies. Patient-derived
xenograft models also recapitulate to some extent an in vivo in-
ﬂammatory response [42], albeit not of human origin. However, xe-
nograft models can be both resource and time consuming, as well as
costly, and require many animals in a time of more and more pressure
to reduce animal experimentation. While it is possible to study the ef-
fects of diﬀerent treatments on cancer stem cells using patient-derived
xenografts, high throughput screening of treatments using xenografts is
not possible and therefore new models that facilitate both the ease of
high throughput of cell lines and both the patient speciﬁcity and a more
realistic architecture of xenografts are required.
2.3. Organotypic tissue slice cultures
The relatively new in vitro techniques of organotypic tissue slice
cultures and organoids somewhat strike a balance in many aspects
between the advantages and disadvantages of both cell lines and in vivo
patient-derived xenografts. Organotypic tissue slice cultures are tissue-
derived slices of varying thickness which, under appropriate conditions,
can be kept in culture for many days to weeks, even months [43,44].
Similar to patient-derived xenografts, organotypic tissue slice cultures
enable treatment assessment on a more personalizes patient-speciﬁc
basis while also maintaining the general histopathological structure and
architecture of the tissue [44]. They are, however, far more diﬃcult to
maintain than traditional cell lines.
Organotypic tissue slice cultures can be easily maintained for short-
term periods and can allow for accurate drug screening [45]. However,
longer term maintenance of organotypic tissue slices is more diﬃcult
[46]. Even with culture media optimization and varying the methods of
culturing (in plate culturing versus on a transwell insert), many orga-
notypic tumor tissue slice cultures are only maintained for up to a
Fig. 1. Comparison of typical laboratory techniques for studying CSC responses. Organoids represent a more realistic response than cancer cell lines in terms of
recapitulating the in vivo environment, and also allow for easier manipulation and high throughput screening than xenografts or slice cultures.
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maximum of 7 days [47,48]. Thus, they do not easily facilitate high
throughput screening of diﬀerent treatments. However, longer orga-
notypic tumor tissue slice culture periods (up to 35 days) have been
reported [49]. While organotypic tissue slice culture techniques were
originally established for normal healthy tissue, protocols have now
also been established for tumor tissue of various diﬀerent origins
[44,45,50,51]. However, although organotypic tissue slice cultures
quantify the response of a (tumor) tissue (or part of a tissue), they do
not give a read-out for the (cancer) stem cell response and therefore
could just be a readout of partial tumor response but not of recurrence
or metastatic potential.
2.4. Organoids
Organoids, three-dimensional in vitro cellular structures derived
from tissue speciﬁc stem cells with the capacity to self-organize into
‘mini-organs’ resembling the tissue of origin [52,53], may bridge the
gaps left by more traditional culturing techniques in addressing the
limitations of cancer stem cells in treatment response prediction. In
comparison to other culturing techniques, organoids are relatively
simple to maintain and expand, and thus oﬀers many alternative means
of assessing treatment responses. Similar to organotypic tissue slice
cultures, the culturing techniques can vary depending on the tissue of
origin (Table 1).
In general, following tissue or biopsy resection, the tissue is en-
zymatically and/or mechanically digested. Culturing protocols fol-
lowing digestion can vary from seeding directly into a Basement
Membrane (BME) [54] to a ﬂoating primary culture followed by
seeding in BME [55] or culture at the air-liquid interface using trans-
well inserts [56]. Organoids can be serially passaged every 1–2 weeks.
Crucially, the media in which organoids are cultured varies, often de-
pending on the tissue of origin. For example, EGF, R-spondin and
noggin are suﬃcient to maintain long-term small intestinal organoids,
while colon-derived organoids require the addition of nicotinamide, the
p38 inhibitor SB202190, prostaglandin E2 and the Alk inhibitor A83-01
[54]. This relative ease for expansion and maintenance of organoids
allows for many alternative means of assessing treatment responses.
However, due to diﬀerences in criteria such as available biopsy size,
biopsy site, organoid expansion rates and cell numbers required, the
passage upon which analysis is performed can vary.
The alterations in cell-cell interactions and the cell-matrix interac-
tions change the in vitro response to many forms of treatment, to a re-
sponse which is more similar to the response seen in vivo than is ob-
served using the more traditional two-dimensional cell culturing
methods [29,32]. Organoids can be more easily manipulated by genetic
modiﬁcation than slice cultures or xenografts [57,58], while organoids
are also more amenable to high throughput drug/treatment testing than
these culture methods [59,60]. Furthermore, microscopy techniques to
visualize organoids and protein localization within three-dimensional
cultures are advancing rapidly [61]. As organoids can be derived from
patient biopsies, patient-speciﬁc responses may potentially be pre-
dicted, with the results guiding medicine towards a more personalized
patient approach. Organoid models have been developed for many
diﬀerent normal tissue types (such as gut [62], salivary glands
[55,63,64], mammary glands [65] and liver [66]), as well as an in-
creasing number of cancer types (including for example breast [59] and
gastrointestinal cancers [54,67]). Despite being a relatively new tech-
nique, both normal tissue stem cell-derived organoids and cancer stem
cell derived organoids have already contributed immensely to the ﬁelds
of cancer biology and personalized medicine.
3. Normal tissue and cancer stem cell organoids in drug and
treatment development
Currently, one of the most well-known organoid systems consist of
the ‘mini-gut’ models developed by Clevers and his colleagues. They
ﬁrst identiﬁed Lgr5 as a marker for gastro-intestinal stem cells [68] and
have since then been able to develop many organoid systems origi-
nating from the gut, including intestinal [62] and colon organoids [54].
Using rectal tissue-derived organoids from cystic ﬁbrosis patients,
Dekkers et al. [69] utilized this system to show the potential of orga-
noids for in disease treatment and understanding by restoring a func-
tional CFTR gene (a cystic ﬁbrosis transmembrane conductance reg-
ulator). Forskolin treatment of organoids from healthy patients resulted
in rapid swelling, while swelling was reduced derived from cystic ﬁ-
brosis patients with a mutation in the CFTR gene [69]. Using a variety
of chemical, temperature-base [69] and gene-editing techniques [70],
they were capable of restoring a functional CFTR gene in organoids
from cystic ﬁbrosis patients. Furthermore, diﬀerential drug responses
between organoids derived from diﬀerent patients were identiﬁed [71].
In terms of cancer treatment and response prediction, organoids
have been shown to accurately represent normal tissue response to
common treatments, such as the chemotherapeutic drug cisplatin [72]
and irradiation [73]. Below we will focus on how organoids have (and
can further) contribute to cancer research, both in disease modelling
and response prediction.
3.1. Organoids to model cancer development and progression
As stated above, organoid systems can be used not only for drug
discovery and treatment response studies, but also in the study of dis-
ease modelling and development. Cancer modelling in particular has
been possible using normal tissue derived organoids. Li et al. [56] de-
monstrated that mutation of Kras and/or loss of p53 induced dysplasia
and hyperproliferation in mouse-derived pancreatic and gastric orga-
noids, and these organoids were capable of forming tumors upon
transplantation into recipient mice. However, to show the oncogenic
requirements of colon-derived organoids, a combination of Apc, Kras,
p53 and Smad4 mutations were required for progression of dysplasia in
vitro and tumor formation upon transplantation, thus showing the ne-
cessity of the multi-hit model of colorectal cancers [56].
Separate from the above study, other groups introduced mutations
in KRAS, TP53, SMAD4 and APC, four genes commonly mutated in
colorectal cancer, into human intestinal tissue stem cells using CRISPR-
Cas9 genome editing techniques [74,75]. By excluding key growth
Table 1
Organoids oﬀer a valuable resource to cancer biology research. Both normal
tissue and tumor-derived organoids can be used as tools for studying many
aspects of cancer biology including drug screening (with a more accurate and
personalized outcome than traditional cell line cultures), cancer development
and disease modeling. Some organoid (healthy and cancer derived) models are
listed above.
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factors from the media, Drost et al. [74] were able to select for mutant
organoids and in vivo transplantation of quadruple mutants into mice
formed aggressive carcinomas. Matano et al. [75] introduced one fur-
ther mutation in PIK3CA. Mutated organoids were again capable of
forming tumors upon xenotransplantation under the mouse kidney
capsule [75]. In both studies, mutant organoids were capable of growth
and expansion in the absence of stimulators of WNT, a key component
of normal intestinal organoid culturing [74,75].
Drost et al. [76] followed up on this study by deleting crucial DNA
repair genes in colon organoids, again using CRISPR-Cas9 methods.
Whole genome sequencing of mismatch repair deﬁcient organoids re-
vealed mutation proﬁles similar to colorectal cancer deﬁcient in the
same pathway, while knock-out of key base excision genes resulted in a
mutation signature previously associated with breast cancer [76]. More
recently, it has been conﬁrmed using pancreatic organoids that KRAS
mutation induces macrophage phenotype changes in pancreatic ductal
adenocarcinoma development [77]. Similarly, mouse-derived gastric
organoids were used to demonstrate that loss of TGF-β receptor 2 in-
duces metastatic tumor evolution and invasion upon in vivo transplan-
tation [78]. Combined, these studies reveal the complexity of the cancer
genome and the processes of cancer regulation, while further high-
lighting the capacity of organoids in furthering our understanding of
cancer development and progression. These studies further contribute
to our understanding of cancer development and progressions, and
studies like these may enable for the discovery of speciﬁc drug targets
for the early treatment, or even prevention, of cancer.
3.2. Tumor tissue-derived organoids
Since the development and optimization of normal tissue organoid
culturing systems, new avenues for drug/treatment development, as
well as means to investigate disease development have opened up.
Furthermore, these systems have been used to show the capacity to
derive organoids from many cancer types. Cancer-derived organoids
oﬀer a potential new means of investigating tumor treatment responses
and could also oﬀer an insight into personalized treatment in the future.
One of the ﬁrst studies to establish organoids from cancer tissue was
that of Sato et al. [54]. Initially, culture conditions were established for
mouse colon crypts and subsequently adapted to allow for the culturing
of organoids derived from the small intestine and colon of human [54].
Further adaption of these protocols enabled them to establish organoid
cultures from colonic adenoma and adenocarcinomas, as well as from
Barrett’s esophagus, a metaplastic malignancy of the esophagus which
is considered a precursor to esophageal adenocarcinoma [54].
Organoid technologies are developing and advancing at an ex-
tremely quick rate, and the available techniques (from survival assays,
ﬂow cytometric analysis, to ﬂuorescent imaging) which can be per-
formed are continually being optimized (some of which are represented
in Fig. 2). Indeed, imaging methods were elegantly optimized to assess
metabolism in cancer organoids derived from both murine and human
tissue following anti-cancer drug treatment [79,80]. Optical metabolic
imaging is based upon the ﬂuorescent nature of nicotinamide adenine
dinucleotide (NAD) and ﬂavin adenine dinucleotide (FAD) upon re-
duction, which can be performed on living tissue samples as a read-out
of metabolic activity within the tissue [81]. This technique was
exploited to demonstrate heterogeneous chemotherapeutic drug re-
sponses in both breast cancer organoids [79] and pancreatic cancer
organoids [80]. Optical metabolic imaging combined with organoids
provides a non-invasive and original means of determining patient-
speciﬁc drug responses, in a potentially high throughput system.
Highlighting the strength of organoid cultures compared to two-
dimensional cell cultures, Jabs et al. [82] developed an automated
microscopy assay to distinguish between cell death and inhibition of
proliferation induced by drugs. Ovarian cancer cells cultured as orga-
noids were compared with ovarian cancer cells cultured in the ‘clas-
sical’ two-dimensional system [82]. Following treatment with clinically
relevant chemotherapeutic drugs, it was found that the eﬀects of the
drugs could be linked to the patients’ genome alterations in organoid
cultures, which in contrast could not be found in monolayer cultures
[82]. Therefore, it seems that such methods to screen relevant drugs
with increased accuracy could help tailor cancer treatments in the fu-
ture to a more personalized treatment plan. Furthermore, these ad-
vancements in the imaging of organoids could also be used to better test
novel drugs or treatments with greater accuracy.
Excitingly, when biopsies are taken for isolation of cancer orga-
noids, it is usually possible to obtain biopsies from normal tissue at the
same time without great inconvenience for the patient. Comparing the
responses of normal tissue derived organoids to those of cancer derived
organoids could potentially oﬀer the opportunity to determine a ther-
apeutic ratio on a personalized basis. Indeed, one study [83] took ad-
vantage of this to complete sequence analysis on organoids derived
from colorectal cancer compared to healthy colorectal tissue derived
from the same patients. As individual organoids are derived from single
cells, it is possible to perform a ‘bulk’ single cell sequencing on orga-
noids [83]. Not only was it found that single cells derived from a single
cancer biopsy showed a high level of mutation variation and a far
greater number of mutations than normal tissue, but even cells from the
same tumor with similar mutation signatures showed noticeably dif-
ferent responses to chemotherapeutic drugs [83]. While diﬀerences in
drug responses at a clonal level exquisitely show the diversity and
heterogeneity within a tumor, assessing the treatment response of or-
ganoids on larger scale (rather than single clones) may be more in-
formative to the response of a tumor as a whole if a more personalized
medicine approach is desired.
Indeed, in a highly promising study for the use of cancer organoids
as a predictor of treatment response, Vlachogiannis et al. [67] cultured
cancer-derived organoids from patients with gastrointestinal metastatic
cancers and treated them with commonly used therapeutics. Patients
were enrolled in Phase I/II clinical trials and the results of the organoid
treatment were compared with the patient’s own response [67]. Mo-
lecular proﬁling of the derived organoids revealed extremely similar
proﬁles to those of the tumors from which they were derived [67].
Furthermore, they could identify diﬀerences between organoids derived
from a patient sensitive to the chemotherapeutic drug regorafenib
compared to organoids derived from a patient resistant to the same
drug. Importantly, they were not only able to mimic inter-patient tumor
diﬀerences using patient-derived organoids but they were also able to
distinguish intra-patient tumor heterogeneity in response to che-
motherapeutic drugs [67]. This study shows the strength of organoids
to predict tumor-speciﬁc responses and is potentially one of the ﬁrst
steps towards a personalized treatment regime based on cancer stem
cell organoids.
As stated earlier, for some cancers (such as esophageal cancers) we
currently lack the optimal tools to accurately predict a response prior to
treatment [13,14]. While great eﬀorts are being made to enhance the
prediction sensitivity of image-based methods, including PET-CT or
magnetic resonance imaging (MRI) [84,85], the recent identiﬁcation of
a subpopulation of esophageal cancer cells with cancer stem cell-like
properties [20], as well as methods to culture esophageal-derived or-
ganoids [86] and adenocarcinoma-derived organoids [54], may allow
for the culturing of esophageal cancer organoids with the potential to
reveal sensitivities that are not detected by these imaging techniques.
The aforementioned studies show the power of organoids to predict a
chemotherapeutic response, while studying the eﬀects of radiation
treatment on organoids is also possible [73]. Esophageal cancer orga-
noids could potentially show inter-patient variability based on the
cancer stem cell populations, which in turn could reveal sensitivity
diﬀerences. Genomic analysis of surviving organoids following radia-
tion and/or chemotherapeutic treatment may provide a ‘cleaner’ re-
sistance signature that could be found in early passage organoids fol-
lowing initial biopsy collection. Furthermore, recent advances in the
optimizing of normal esophageal tissue organoids culturing [87] may
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allow for prediction of a ‘personalized therapeutic ratio’.
Pancreatic cancer is also known to be a notoriously diﬃcult cancer
to predict and treat [88]. However, although some very illuminating
patient-derived xenograft models [89] and animals [90] have been
established, there is still a need for more complementary preclinical
tools for assessing response, as these models are expensive and can’t be
used to quickly determine/predict patient responses. Recent develop-
ments in culturing of pancreatic ductal adenocarcinoma organoids
which physiologically resemble the development of pancreatic cancer
[91] may address some of the drawbacks of the current models.
An exciting new development in the ﬁeld of organoids is the crea-
tion of “Living biobanks”. These depositories have been proposed/cre-
ated for tumors of various origin, including breast, colorectal and
bladder [59,60,92,93], to enable access to organoid systems on a larger
scale. Biobanks of patient-derived cancer organoids have the potential
to be accessible worldwide to advance research and treatment. Since
organoid cultures mimic the heterogeneity of cancer subtypes better
than cell lines, biobanks could potentially oﬀer a platform for treatment
screening with a more personalized response. Organoid depositories
can better encompass the genetic diversity between tumors which can
be used to identify speciﬁc drug-genetics interactions.
Although less work has been performed on organoids derived from
cancers than normal tissue, the work is highly revealing and indicative
of a strong future for organoids in cancer biology research. The ad-
vantages of more accurate response prediction than traditional two-
dimensional cell culture models, the capacity to reveal heterogeneity
even within individual patients, combined with the more facile nature
of high throughput screening than xenografts, should enable organoids
to take their place amongst the most important tools for prediction of
cancer treatment responses in the future. The majority of cancer orga-
noid models are limited to adenocarcinomas, and thus far less oppor-
tunities are currently available for squamous cell carcinomas for in-
stance. However, as our knowledge of cancer development expands,
and more cancer stem cell markers are identiﬁed, organoids can only
become a stronger research tool covering all cancer types.
3.3. Limitations of organoid models
While organoid models potentially oﬀer new insights into the de-
velopment and treatment of cancer, they are not the ﬁnal piece in the
puzzle and many limitations to organoid models still remain. Cancer
development and treatment responses are highly complex processes
that involve many other factors. Tumors are, in general, highly vascu-
larized. These blood vessels further inﬂuence the response of cancer to
treatment [40]. Furthermore, treatment response is also inﬂuenced by
the tumor microenvironment, such as localized regions of hypoxia [94],
and by the surrounding immune system [95]. While tumor organoids
can be cultured under hypoxic conditions, this can’t recapitulate the
diﬀering gradients of hypoxia found within a tumor. Growth factors and
cytokines can be added to media to elicit an immune response. How-
ever, this remains a highly artiﬁcial response. In the future, it may be
interesting to perform co-cultures with blood vessels and immune cells
to further mimic a truer environment of the tumor, and thus capture a
more realistic tumor treatment response. Despite these limitations the
results from organoid cultures faithfully recapitulate the in vivo re-
sponse of patient-derived xenograft models, as shown in recent studies
by Pauli et al. [92] and Lee et al. [93] using bladder cancer-derived
organoids.
4. Concluding remarks
Organoids, derived from both normal tissue stem cells and cancer
stem cells, have advanced our understanding of both disease develop-
ment and drug discovery. They have added to our wealth of knowledge
already obtained from decades of priceless work using the more tradi-
tional two-dimensional cell lines. The added complexity of organoids,
with their diﬀerent cell-cell interactions, cell-matrix interactions and
the potential for cellular diﬀerentiation within organoid cultures
[29,30], have complemented and strengthened this data, while also
enabling us to overcome some of the limitations of cell lines, such as an
overestimation of drug and irradiation responses [52,53,73]. The het-
erogeneity of cell subtypes found in organoids, and their treatment
responses being more similar to in vivo than those seen in cell lines,
means that organoids can also be used to potentially test new upcoming
cancer treatments, such as immunotherapy [6–8], with higher accu-
racy, while organoids also oﬀer a more reliable platform for assessing
drug responses of ‘new’ drugs which can be identiﬁed by genetic pro-
ﬁling on a personalized basis [96]. As mentioned above, extending the
therapeutic window of treatment is the primary aim of drug and/or
irradiation treatment studies. Comparing the response of tumor-derived
organoids from a patient with the response of normal tissue derived
organoids from the same patient, or possibly even co-cultures of the
two, could in the future oﬀer a predictive therapeutic window on an
individual personalized basis. The initiation of accessible organoid
biobanks for research purposes similar to cell line depositories can only
further advance our understanding of the role of cancer stem cells in
therapeutic responses [59,60,92,93].
Fig. 2. The possibilities with (tumor) organoids. Following biopsy collection, cells can be isolated and cultured as organoids. Many read-outs can be obtained using
organoid technologies. Genomic proﬁling can be used to identify new drug targets [96] from the biopsy/early passage organoids, mutations following treatment [93]
or to potentially identify treatment resistance signatures of cancer stem cells in treated organoids. Techniques such as survival assays [73], histological [93] or
immunoﬂuorescent staining [61] and optical metabolic imaging (OMI) [79,80] can also be performed on cultured/treated organoids.
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